Sanofi-GSK COVID-19 Shot Will Cost Around $11

Sanofi is planning to price its recombinant protein-based COVID-19 vaccine developed with a GlaxoSmithKline (GSK) adjuvant at approximately $11 a dose.

Phase 3 trials on a reformulated version of the Sanofi-GSK vaccine candidate began in May and the companies are now also assessing booster jabs. Full trial results are expected by year’s end.

Sanofi and GSK have fallen behind in the race to develop COVID-19 vaccines but are looking to pick up steam heading into 2022 by offering a price comparable to the discounted price of $10 per dose that Pfizer-BioNTech and Johnson & Johnson previously offered in their supply deals.